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Abstract: The best-characterized members of the M23 family are glycyl-glycine hydrolases, such as
lysostaphin (Lss) from Staphylococcus simulans or LytM from Staphylococcus aureus. Recently, enzymes
with broad specificities were reported, such as EnpACD from Enterococcus faecalis, that cleaves D,L
peptide bond between the stem peptide and a cross-bridge. Previously, the activity of EnpACD was
demonstrated only on isolated peptidoglycan fragments. Herein we report conditions in which
EnpACD lyses bacterial cells live with very high efficiency demonstrating great bacteriolytic potential,
though limited to a low ionic strength environment. We have solved the structure of the EnpACD
H109A inactive variant and analyzed it in the context of related peptidoglycan hydrolases structures
to reveal the bases for the specificity determination. All M23 structures share a very conserved
β-sheet core which constitutes the rigid bottom of the substrate-binding groove and active site,
while variable loops create the walls of the deep and narrow binding cleft. A detailed analysis of
the binding groove architecture, specificity of M23 enzymes and D,L peptidases demonstrates that
the substrate groove, which is particularly deep and narrow, is accessible preferably for peptides
composed of amino acids with short side chains or subsequent L and D-isomers. As a result, the
bottom of the groove is involved in interactions with the main chain of the substrate while the side
chains are protruding in one plane towards the groove opening. We concluded that the selectivity of
the substrates is based on their conformations allowed only for polyglycine chains and alternating
chirality of the amino acids.
Keywords: peptidoglycan hydrolase; M23 peptidase; Enterococcus faecalis; endopeptidase
1. Introduction
Peptidoglycan (PG) is a major component of bacterial cell walls providing cell shape
and resistance to the internal turgor pressure. Furthermore, it serves as a scaffold for
the attachment of proteins and cell wall anionic polymers, such as teichoic acids. The
PG network consists of repeating units of disaccharides, stem peptides and cross-bridges
(Figure 1A). Stem peptides are made of both L- and D-amino acids, and their sequence is
usually conserved among the genera. They are cross-linked directly in most Gram-negative
and in some cases of Gram-positive bacteria such as Streptococcus oralis or Aerococcus
viridans. In Gram-positive bacteria length and composition of the interpeptides vary;
e.g., in S. aureus they consist of five glycines, while in E. faecalis there are two L-alanine
residues [1].
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Figure 1. Schematic representations of E. faecalis peptidoglycan (A) and EnpA modular organization
(B). (A) Cross-linked peptidoglycan monomers (black) and other elements of PG (gray); EnpACD
cleavage site is marked with red dash arrow. (B) Domain organization of EnpA; numbers represent
amino acid positions in a full-length protein.
Most bacterial genomes encode a large number of hydrolytic enzymes that target virtu-
ally every bond present in PG [2]. These enzymes are not only required for the remodeling
of normal cell walls during growth and division but also are used as weapons to compete
with other bacterial strains living in the same ecological niche. Peptidoglycan hydrolases
are used by bacteriophages to enter bacterial cells and to release the progeny at the end
of the phage life cycle. Consequently, they are acquiring increasing attention as a poten-
tial weapon against pathogenic bacteria, particularly those resistant to antibiotics [3–9].
Among peptidoglycan hydrolases are endopeptidases belonging to the M23 MEROPS
family [10], such as lysostaphin and LytM that cleave pentaglycine cross-bridges present in
staphylococcal PG. Members of the M23 family are metallopeptidases containing a zinc
ion in their active site, coordinated by two histidine and one aspartic acid residues in the
conserved motifs: HXXXD and HXH [11–15]. Some members of this family have also
shown to be potent antimicrobial agents that could be applied to eliminate staphylococci,
particularly antibiotic-resistant strains [3,4,16,17].
Enzymatic activity of the M23 domain from E. faecalis protein called EnpA was re-
ported previously [18]. E. faecalis is a Gram-positive bacterium inhabiting the intestinal
tract of healthy humans and animals. As an opportunistic pathogen, it can cause various
infectious diseases, such as urinary infections, bacteremia and endocarditis [19–21]. EnpA
is a prophage encoded 1721 residues protein composed of three domains (Figure 1B); the
N-terminal domain (1350 amino acids) shares homology with phage tail tape measure
proteins. The two domains located towards the C-terminus of EnpA are homologous to
domains belonging to PG hydrolases with lytic transglycosylase activity (cleaving glycan
chains) and M23 peptidase activity (cleaving PG peptides). The functional analysis of
the EnpA catalytic domain (EnpACD) revealed its hydrolytic activity on the D-Ala–L-Ala
bond, which is characteristic for E. faecalis peptidoglycan, and proposed the minimum
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substrate of EnpCD to consist of three residues of the donor stem and the amino acids of
the cross-bridge [18].
Herein we report a crystal structure of M23 D,L-endopeptidase EnpACD, and discuss
its place among other characterized M23 peptidases in terms of the structural–functional
relationship. Moreover, we demonstrate the potent lytic activity of EnpACD against the
range of bacterial species.
2. Results
2.1. EnpACD Structure Determination
Despite multiple attempts to crystallize and solve the EnpACD structure, we were
unable to obtain crystals of the wild-type protein diffracting below 4 Å; therefore, we
generated an inactive variant of EnpACD H109A. The crystals of this variant gave better
diffraction data that were then used to solve the structure of EnpACD at a resolution of 3 Å.
The crystal structure revealed five protein molecules in the asymmetric unit (ASU).
Each single protein molecule covered from 127 to 129 amino acids depending on observed
electron density. All EnpACD molecules in the ASU are similar with root-mean-square
deviation (RMSD) values of 0.35 Å–0.65 Å and β-factors for chains A–E ranging from 87 to
108 Å2. A weaker density is observed for the part of the protein described as loop 1 that is
partially disordered has the highest B-factor. Thus, further structure description refers to
chain A unless stated otherwise.
According to the Matthews analysis, the solvent content of the measured crystal was
about 80%. There is only 0.35% of all structures deposited in Protein Data Bank (PDB)
that have 80% or more solvent content in the crystal (as of August 2020) [22]. The limited
number of intermolecular interactions in high solvent content crystals could be responsible
for weak diffraction power and low resolution of the structure herein presented. The crystal
packing is presented in Figure S1.
2.2. Overall Structure of EnpACD
EnpACD is a globular all β-structure molecule that could be divided into two β-sheets.
The smaller 3-stranded β-sheet, composed of strands β3, β9 and β7, runs parallel to the
central 7-stranded antiparallel β-sheet. The latter contains a conserved core region for LAS
enzymes [15]-strands assigned here as β1, β2, β10 and β6 with zinc chelating residues
located on or in close vicinity of β2 and β10 (Figure 2A).
A central β-sheet creates the bottom of the active site groove while its walls are re-
stricted by three out of four protruding loops, as loop 4 rather sticks to the protein core. The
loops were described previously in other members of the M23 family: lysostaphin, LytM
or LasA [11,12,23] and are analogously assigned herein: loop 1 (Asp17–Gly31, connecting
strand β1 and β2), loop 2 (Ser55–Gly61, connecting strands β4 and β5), loop 3 (Gly100–
Pro108, connecting strand β9 and β10) and loop 4 (Gly117–Gln122, connecting strands β10
and β11). Loop 1 is the longest among all and participates in interactions with neighboring
protein molecules in the crystal. In spite of two short antiparallel β-strands that can be
distinguished halfway, the tip of the loop is characterized by the highest B-factor exceeding
150 Å2. The superposition of all molecules in the ASU confirms that loop 1 is the most
flexible element in the EnpACD structure.





Figure 2. Structure of EnpACD and its active site architecture. (A) Cartoon representation of the
secondary structure elements. β-sheets are colored red and labeled; The position of the loops are
marked by grey ellipses and colored yellow, blue, cyan and dark grey, respectively, for loops 1–4;
other are colored grey. The ligands of the Zn2+ ion (green sphere) are shown as yellow sticks and
labeled. (B) Residues coordinating Zn2+ ion and taking part in catalysis are shown as sticks and
labeled. Interactions between residues are shown as dashed black lines. The side chain of His109 is
marked in gray as it is modeled on a position of Ala residue.
2.3. The Architecture of Active Site and Binding Groove
The organization of the active site is conserved among the members of the enzymati-
cally active peptidoglycan hydrolases from the M23 family, and a strong electron density
corresponding to a metal ion was observed in the close vicinity of His29, Asp33 and His111,
residues coordinating Zn2+ (Figure 2). The presence of Zn2+ ions in the protein was
confirmed by an X-ray fluorescence scan (data not shown). The identified zinc ligands
are stabilized by interactions with structurally adjacent residues: Nδ of His29 hydrogen
binds the carboxyl oxygen of Gly31, while His111 binds Oε of Glu113 (Figure 2B). The
insufficient resolution of the data set and high atomic displacement parameters do not
allow interpretation of the whole difference electron density close to the Zn2+ (Figure S2).
EnpACD substrate pocket is placed on the plane of the central β-sheet, and its walls
are defined by loops that build a deep (10–20 Å) and very narrow (4–5 Å) groove (Figure 3).
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Figure 3. Surface representation of the EnpACD substrate-binding groove. The colors yellow, blue, cyan and grey depict
loops 1–4, respectively. The approximate dimensions of the restricted part of the groove are shown. Loop 4 is positioned
close to the protein core rather than taking part in a groove forming. The metal ion is presented as a green sphere.
2.4. Structural Comparison with Other Members of M23 Family
Chain A of the presented EnpACD structure was used as a search model in the Dali
protein structure comparison server [24]. A structural relationship of Z-score ranging from
10 to 18.4 was found with 15 other protein structures (Table S1). Additionally, an NMR
structure of LytU [25] was added as closely related to EnpACD with RMSD of 1.9 Å. Only
entries with defined activity (highlighted with grey background) were used for comparison
and further structural analysis.
Two clusters can be distinguished in the superimposed structures; the first is the highly
conserved core composed of β-strands that comprise the bottom of the active side (Figure
S3a) and a substrate groove which is built of variable loops (Figure S3b). Interestingly, the
amino acid sequence conservation in the protein core is restricted only to residues taking
part in catalysis and few hydrophobic amino acids.
2.5. Specificity and Bacteriolytic Activity of EnpACD
EnpA was shown to cleave bonds between stem peptide’s D-Ala and the cross-bridge’s
L-Ala or L-Gly residues [18]. However, no EnpACD activity was reported on intact PG of
bacterial sacculi or whole cells so far.
We have defined conditions in which EnpACD demonstrates a potent bacteriolytic
activity on living bacterial cells of diverse species. First, we tested the bacteriolytic activity
of EnpACD in various conditions and concentrations of the enzyme in turbidity reduction
assays (Figure 4A and Figure S4). The results demonstrate that EnpACD has potent bac-
teriolytic activity in a wide range of temperatures, but only in low ionic strength buffers
(Figure 4A,B, Figures S4 and S5). In optimal conditions, 500 nM EnpACD is able to eliminate
up to 107 cells of S. aureus at room temperature just in one hour, demonstrating the modest
bacteriolytic activity, particularly compared to lysostaphin and LytMCD (Figure 4B).
Once the reaction conditions allowing monitoring of the bacteriolytic activity were
established, we verified if the specificity of the enzyme previously determined on short
fragments of peptidoglycan [18] would be sustained in assays with whole, live bacterial
cells.
We evaluated the bacteriolytic activity of EnpACD on 32 different bacterial strains
of the diverse composition of peptidoglycans and other components of the cell walls
(Table S2).
In the cases of direct peptidoglycan cross-linking, such as in Streptococcus oralis and
Bacillus subtilis, no activity was recorded, while low activity was noted against Aerococcus
viridans. Moreover, strains with PG cross-linked via D-Asp, Enterococcus faecium and
Lactococcus lactis, were not lysed by EnpACD. A low activity of EnpACD was observed in
the case of Streptococcus ratti with L-Thr–L-Ala in the cross-bridge. Moreover, EnpACD
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displayed activity against Micrococcus luteus. Although classified sometimes as having
direct cross-links, M. luteus cross-bridge has a composition of the stem peptide: D-Ala-L-
Ala-D-Glu(Gly)-γL-Lys-D-Ala-ε-L-Lys [1]. Most of the strains with cross-bridges composed
of glycine, serine and alanine residues, either alone or in various combinations, were
effectively lysed by EnpACD. Overall, the specificity of EnpACD demonstrated on isolated
substrate fragments is sustained when the whole cells are used in assays conducted in low
ionic strength conditions.
Figure 4. Bacteriolytic activity of EnpACD on S. aureus 8325-4 strain measured in turbidity reduction
assay (A,B) or reduction of CFU/mL (C) (A) bacteriolytic activity of 500 nM EnpACD in buffers
of various conductivity (indicated as red lines) (B) bactericidal activity of EnpACD, LytMCD and
mature lysostaphin presented as number of bacterial cells that survived 1 h incubation with the
enzymes (LytMCD 100nM, Lss 100nM, EnpACD 500 nM) at room temperature starting from 106, 107
or 108 CFU/mL. No enzyme was added to the controls; the number of bacterial cells was determined
by plating of serial dilutions on TSB plates. Each experiment was repeated three times using an
enzyme from the same preparation and different bacterial cultures. Three technical repetitions were
performed each time.
Although a strong correlation between the presence of the cross-bridge and EnpACD
activity was recorded, this conclusion is not completely unambiguous. We could observe
differences in EnpACD specificity towards bacterial strains, for which the same composition
of cross-bridges is reported indicating that the composition of the cross-bridges is very
important but probably not the only determinant of the EnpACD specificity. EnpACD
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cleaves bonds in the junction of donor stem peptide and cross-bridge; thus also stem
peptide sequence may play a role in substrate specificity determination.
According to Schechter nomenclature [26], the positions (P) on the peptide substrate
are counted on both sites of the scissile bond (Figure 5). The binding groove is composed
of subsites, split into two groups (S and S’) located on both sites of the active center, and
each of them accommodates one amino acid of the substrate. D-Ala was present at position
P1 of all tested peptidoglycan substrates that were cleaved by EnpACD [1,18]. Neither
our results nor previously published observation on isolated substrates [18] support any
straightforward, direct correlation between the presence of particular amino acids at the
positions P2 and P3 of the stem and the enzyme specificity.
In the light of the presented results and observations published previously, we can
postulate that both, amino acids of the cross-bridge and the stem peptide, might be involved
in the determination of the enzyme specificity.
γ ε
Figure 5. Schematic representation of EnpACD cleavage site and specificity at particular positions on both sites of the scissile
bond (based on the specificity determination presented in Table S2).
The bacteriolytic activity of EnpACD can be utilized for various applications. The
medical applications of M23 enzymes, such as lysostaphin, are jeopardized by the resistance
mechanisms that already exist in nature. One of them is linked to the shortening of the
pentaglycine bridge, the other to the substitution of glycines with serines [27–29]. We have
confirmed that such alteration of the staphylococcal cross-bridge does not hamper the
bacteriolytic activity of EnpACD (Figure S6a,b), and therefore this enzyme can be used in
the case lysostaphin resistance spreads.
To check the relevance of other cell wall polymers on EnpA activity, we ran a set
of experiments to determine the role of teichoic acids (TA) as an important player in the
regulation of peptidoglycan hydrolase activity [30,31]. We observed that the activity of
EnpACD was significantly decreased when bacterial strains were depleted of teichoic acids,
e.g., in the S. aureus mutant strain lacking TA (∆tagO) and strains depleted of TA by
tunicamycin, an inhibitor of TA synthesis (Figure S6c) [32].
2.6. Substrate Binding Model to EnpACD Reveals Possible Interactions
Numerous trials to co-crystalize EnpACD inactive form with various substrate frag-
ments and soaking of preformed crystals with substrates was disappointingly unsuccessful;
therefore, we decided to manually dock the substrate (L-Lys-D-Ala-L-Ala-L-Ala) into the
binding groove of EnpACD based on the homology modeling (Figure 6).





Figure 6. Surface representation of EnpACD substrate-binding groove with a modeled substrate
(L-Lys-D-Ala-L-Ala-L-Ala), shown as stick and ball model. The colors yellow, blue, green and grey
shows the loops 1–4, respectively. The right panel shows the zoom of the bonded substrate. Residues
speculated to interact with the substrate are shown as yellow sticks. The positions of substrate amino
acids are depicted by the dashed ellipses and labeled in dark blue.
P2/S2. The S2 subsite of E. facelis EnpACD, is occupied by the lysine residue of the
substrate (P2). The bottom of the S2 subsite is defined by the side chain of His109. There is
a branched groove on the S2 subsite that could accommodate lysine residue with a long
side-chain; however, the modeled position of the main and side chains might be reversed.
It is worth noting that in the case of LytM, the non-primed site of the ligand was also
modeled tentatively in two different conformations [33].
P1/S1. The bottom of the S1 subsite is defined by the zinc ion, its ligands and His78.
This subsite in EnpACD is less restricted than in LytM or Lss structures; the Arg21 side
chain is moved away from the scissile bond, while in LytM or Lss tyrosine at corresponding
position directs its side chain towards the active site. Moreover, EnpACD S1 subsite widens
towards the top and hence is accessible for the side chain of alanine residue, in contrast to
Lss where loop 1 might restrict the active site from the top [12,34].
P1′/S1′. The prime subsite, defined by side parts of the loops 1 and 3, becomes broader
and rather shallow starting from S1′. In the structure of VanXYg dipeptidase, where Arg74
is present in a position corresponding to Arg21 of EnpACD, the carbonyl oxygen of Ala at
P1′ interacts with the Arg74 residue [35]. Similar arrangements of surrounding residues
in EnpACD lead us to propose similar interaction, where carbonyl oxygen of P1 alanine is
stretched between Arg21 and Asp27 while its side-chain points towards the hydrophobic
ring of Trp104. The S1′ subsite can be extended by the movement of the side chain of
Trp104, which is solvent-exposed.
P2′/S2′ EnpACD has a unique Leu60 residue that contributes to S2′ subsite securing
hydrophobic interactions with the 2nd L-Ala side-chain at position P2′ or long aliphatic
side-chain of Nε bound L-Lys at P3′. In this part, the binding groove becomes wide and
open.
3. Discussion
3.1. EnpACD Displays a Potent Antibacterial Activity
Our results demonstrate that EnpACD has a great bacteriolytic potential that could be
used to eliminate certain pathogens, as it was demonstrated for some of the other known
peptidoglycan hydrolases, for instance, lysostaphin or LytM [8,36–39]. The activity of
these two aforementioned enzymes is restricted to glycyl–glycine bonds characteristic for
staphylococcal cross-bridges. Unlike them, EnpACD has broader specificity [18], similar to
zoocinA (ZooA) from Streptococcus zooepidemicus [40].
EnpACD can effectively lyse living bacterial cells but only in low ionic strength condi-
tions, similarly to the isolated catalytic domain of other members of the M23 family, LytM
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and lysostaphin [36,41]. Nevertheless, such a limitation can be overcome by attachment of
cell wall binding domain, as it was previously demonstrated for LytM catalytic domain
fused to CWT from lysostaphin that increased the enzyme affinity to bacterial cell walls,
leading to efficient lysis of bacterial cells also in physiological conditions [41,42]. This
approach could also be considered to expand the tolerance of EnpA to ionic conditions. Im-
portantly, unlike lysostaphin and LytMCD, EnpACD can accommodate serine at Pl’ or/and
P3′positions.
3.2. General Architecture of the Binding Groove of M23 Reflects Enzyme Specificity
To understand the rules governing the specificity in M23 family enzymes, we analyzed
the architecture of binding grooves of newly solved EnpA structure and compared it with
structurally related M23 peptidases with reported activity (Figure 7). In M23 proteins, loop
1 and loop 3 build the walls of the active site and create a high and narrow canyon-like
entrance on the S1 and S1′ binding subsites with a location of the scissile bond in between.
In fact, those subsites look very similar in all the analyzed structures. In contrast, the
architecture of the further part of the prime site is much more diverse as a result of the
flexibility and substantial structural diversity of loops 2 and 4 [34].
EnpACD S1 subsite is selective towards D-Ala, the 4th residue of the donor stem
peptide (Figure 5). S1′ subsite is less restrictive and can accept such amino acids as glycine,
alanine or even lysine via ε amino group but not aspartic acid, while S2′ can accommodate
small amino acids (glycine, alanine) or residues with longer side chains but only in D-
configuration, often found in bacterial peptidoglycans. The alternating occurrence of
L and D amino acids results in an unusual spatial arrangement of the peptides due to
increased flexibility of the main chain allowing the side chains to be positioned on one side
of the peptide [43]. Only such substrate can fit into a flat binding groove of peptidoglycan
hydrolases from the M23 family.
M23 enzymes that share a strong preference towards pentaglycine substrates, such as LytM,
lysostaphin and LytU, have elongated, deep and narrow binding grooves [11,12,14,25,33]. The
EnpA broader specificity is achieved by opening the binding groove at the prime site
making it more accessible for a wider range of substrates [44,45]. Moreover, in contrast
to lysostaphin and LytMCD, EnpACD can accommodate serine at Pl’ or/and P3′ positions.
This is a unique and important feature as serine at this position results in resistance of the
host against lysostaphin and other glycyl–glycine M23 endopeptidases and is a naturally
occurring mechanism of resistance to these enzymes [27,28,46–48].
The LasA substrate groove is significantly shorter and shallow at the prime subsite
what corresponds well to the specificity of LasA that is broaden compared to the afore-
mentioned enzymes [23]. The LasA enzyme was shown to tolerate aromatic or branched
amino acids at the P1′ position, however not at P2′ [23,49]. The substrate grooves of Gp13
and Csd3 enzymes are less restricted at the prime subsite. Both enzymes cleave peptide
bond between mDAP and D-Ala, and the architecture of their binding grooves shows
that there is enough space at S1 and S2 subsites to accommodate bulkier residue, such as
mDAP [50–52].
We also analyzed the binding of similar substrates by structurally related enzymes
from the LAS family [15]. Substrate binding studies of the VanXY protein have shown that
the full tetrapeptide of a donor stem peptide is needed for optimal activity [35], similarly to
previously reported data for minimal EnpACD substrate [18]. The data show that in both,
EnpACD and VanXY, the stem peptide interacts with the part of protein close to S2 binding
subsite and that there is great variability of substrates residues in P1′ position. VanX
displays activity on D,D- and D,L- dipeptides (D-Ala-D-Ala; D-Ala-D-Phe; D-Ala-L-Gly,
DL-Ala-DL-Ser, DL-Ala-DL-Val; DL-Ala-DL-Asn) but is not active against tripeptides and
L,L-dipeptides [53].
Some similarities in binding groove architecture are also observed in other enzymes
with similar specificity to EnpA. CHAPK domain of the endolysin LysK from S. aureus
bacteriophage K is not a member of the M23 family, but like EnpA, it cleaves bonds between
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D-Ala of the peptidoglycan stem peptide and a glycine of the cross-bridge. Although the
overall structure of this peptidase (pdb ID: 4CSH) is very different, the architecture of the
binding groove resembles the one of EnpA [54] (Figure S7).
Figure 7. Surface representation of selected proteins from M23 family. The peptide binding sites
in the groove are derived from homology modeling of LytM with ligand structure (4ZYB) and are
visualized by the black spheres, from left to right from P2, P1, P1′ to P2′. The size and the volume of
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the binding groove restricted by the neighboring loops are shown by the grey mesh. The volume of
the pockets was detected automatically as a potential binding pocket [55] and are 547 Å3, 616 Å3,
472 Å3, 553 Å3, 413 Å3, 404 Å3, 386 Å3 and 275 Å3 for LytM, Lss, LasA, LytU, EnpA, ZooA, Gp13
and Csd,3 accordingly. The grey surfaces in Gp13 and Csd3 supplement the originally unmodelled
elements in the structure. They were placed based on the homology modeling and are composed of
glycine residues in order to avoid modeling of the side chains. The double-headed arrow in EnpACD
and ZooA structures shows the widening of the substrate-binding groove in the far prime region.
This analysis brought us to the conclusion that the substrate specificity of the M23
enzymes is determined by the general architecture of the binding groove, which in the
proximity of the active site is narrow and deep while its bottom is based on a flat β-sheet.
Only interactions between the substrate main chain and the bottom of the groove are
possible as the structure does not provide space for the side chains. As a consequence,
substrates have to be built either of residues that have no or short side chains and/or have
alternating L and D amino acids that increase the main chain flexibility. In other words, the
substrate selectivity seems to be based on spatial configurations that allowed for glycine
residues and the chirality of amino acids, but the complex structure with the substrate
would be needed to confirm these conclusions.
3.3. Arginine 21 Plays a Role in EnpA Activity
Apart from the conserved zinc-binding residues, other amino acids were proposed
to play a crucial role in M23 enzymes, such as Tyr204 in LytM [33] or Tyr151 in LasA [23].
In some M23 enzymes, the corresponding position is occupied by other residues, such
as glutamine in Gp13 or arginine in Csd3 and EnpACD (Figure S8). Arginine residues
are also found at this position in other enzymes grouped together with M23 as the LAS
family [15], which also comprises enzymes cleaving D-Ala–D-Ala bonds (carboxypeptidase
from Streptomyces albus, PDB id: 1LBU [56], peptidase VanY from E. faecium, PDB id: 5HNM,
VanXYg dipeptidase from E. faecalis, PDB id: 4MUQ [35] or VanXYc from Enterococcus
gallinarium (PDB id: 4OAK)).
In the EnpACD structure, the Arg21 side chain is in close contact with Ser16 and Asp27,
suggesting the formation of the hydrogen bond and a salt bridge. The equivalents of
these two residues are usually present together also in other M23 proteins, thus might be
structurally important as demonstrated for VanXYg, where the amide nitrogen of Gln79,
a residue that corresponds to the Asp27 in EnpA, was suggested to be necessary for
catalysis (Figure 8) [35]. In LytM, a Tyr204 was proposed to play a role in stabilization of
the substrate transition state during cleavage reaction [33], while the guanidinium group
of arginine occupying an equivalent position in some carboxypeptidases was proposed
to act as electrophilic catalyst interacting with transition state oxyanion [57]. Contrary
to the tyrosine residues, arginine can form separate hydrogen bonds, positioning other
residues around the active site and stabilizing its geometry while binding the substrate at
the same time [57]. Such additional bonds created by arginine are important for EnpACD
activity, as substitution of R21Y inactivated the enzyme but did not influence its structure
(Figure S9a,b).
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Figure 8. The active site of (A) EnpA, (B) VanXYg with phosphinate dipeptide (PDB id: 4MUQ), (C)
Vibrio cholerae M23 (PDB id: 2GU1) and (D) LytM with phosphinate tetraglycine (PDB id: 4ZYB).
There is a striking similarity between residues arrangement around the active site of A, B and C
(shaded area). The hydrogen bonds between residues and ligands are shown as dashed lines. Zinc
ion is presented as a green sphere.
4. Materials and Methods
4.1. Gene Cloning
The DNA encoding the EnpACD H109A was obtained by gene synthesis and cloned
as a NcoI-BamHI fragment in pET2818.
4.2. Mutagenesis
Two single mutations were introduced into the EnpACD gene: A109H substitution re-
stored the wild type of the enzyme and R21Y generated in the WT background. PCR-based
site-directed mutagenesis was performed using Phusion high-fidelity DNA polymerase
(Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s 3-step protocol.
The plasmids were used to transform E. coli TOP10 host cells, and the selected clones were
verified by DNA sequencing.
4.3. Protein Purification
The expression of wild-type EnpACD and proteins with H109A or R21Y substitutions
was carried out in E. coli BL21(DE3). Transformed bacteria were grown in auto-inducting
LB broth with 50 µg/mL ampicillin overnight at 25 ◦C and vigorous shaking. The cells
were centrifuged at 4000 rcf for 10 min and then resuspended in buffer A (50 mM TrisHCl
pH 8,0, 500 mM NaCl, 20 mM imidazole, 10% glycerol). Bacteria suspension was sonicated
on ice for 5 min (cycle: 15 s work, 60 s rest) and centrifuged 145k rcf for 40 min at 4 ◦C.
The supernatant was loaded on HisTrap HP 5ml column (GE Healthcare), washed in
buffer A, and gradually eluted to buffer B (20 mM TrisHCl pH 8,0; 200 mM NaCl, 500 mM
imidazole; 10% glycerol). Fractions containing overexpressed protein were concentrated
and loaded on the 26/600 Superdex 75 prep grade, size-exclusion chromatography column
(GE Healthcare). The separation was performed in buffer B without imidazole. The peak
fractions were analyzed by SDS-PAGE. Pure protein was concentrated, flash frozen and
stored at −80 ◦C.
4.4. EnpACD H109A Crystallization
EnpACD H109A crystals were grown using the sitting-drop vapor-diffusion method
at 291 K. A crystallization robot (Phoenix, Art Robbins Instruments) was used to mix
0.2 µL of JCSG-plus screen buffers (Molecular Dimensions) with an equal volume of
15 mg/mL protein solution in 50 mM Tris-HCl buffer pH 7.5 and 200 mM NaCl on 96-well
crystallization plates (Molecular Dimensions). The crystals appeared after 3 days in a buffer
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consisting of 0.8 M succinic acid, pH 7.0. Crystallization in this condition was repeated on
a 24-well Cryschem Plate (Hampton Research) by mixing 4.0 µL of 9.8 g/L protein solution
with 2.0 µL of well solution. Again, the crystals appeared after 3 days and were harvested
on 10th day, when they reached the largest size (co-crystallization with pentaglycine was
also attempted, but no crystals were obtained). The crystals were cryo-protected by quickly
immersing in the well solution mixed in a 1:1 volume ratio with 50% (v/v) glycerol and
flash cooled in liquid nitrogen.
4.5. Data Collection, Processing
EnpACD X-ray diffraction data set were collected at beamline P13 operated by EMBL
Hamburg unit at the PETRA III storage ring (DESY, Hamburg, Germany) using the PILA-
TUS 6M detector [58]. The data were integrated and scaled using the XDSAPP software [59].
All relevant data collection and processing statistics are presented in Table S3.
4.6. Structure Determination and Refinement
Firstly, the search model of NMB0315 from Neisseria meningitidis (PDB ID: 3SLU) [60]
was chosen based on the highest amino acid sequence homology. Upon sequence alignment
analysis, the model was truncated to residues 294–387 and was used for molecular replace-
ment. According to the Matthews correlation coefficient, initially, 10 protein molecules were
searched in the asymmetric unit (ASU), which corresponds to the 57.8% solvent content [61].
However, only two protein molecules were found using the Phaser software [62], indicating
more than 91% solvent content in the crystal. A subsequent structure refinement gave
high R values: 0.56/0.58 (Rwork/Rfree). In the following phasing round, the protein model
predicted by I-Tasser with a primary sequence consistent with the EnpACD protein [57]
was used with similar results. Although the initial R factors were suggesting a completely
random solution, the electron density was convincing for both protein molecules and
sufficient enough for moderate manual structure refinement using Coot software [63]. The
electron density peaks greater than 13σ were identified. Their position close to the active
site residues coordinating the Zn ion in a reference structure indicated that the obtained
results are at least partially correct. The refined structure was used for the localization
of further copies of EnpACD in the ASU with no success. Therefore, the symmetry was
reduced from P6522 to P65, and molecular replacement was performed again. 10 protein
molecules were found in the ASU, and initial refinement resulted in R values: 0.37/0.42
(Rwork/Rfree). Further inspection with the Zanuda software indicated that the P65 space
group was incorrect and suggested changing it back to P6522. Subsequently, the structure
was successfully refined in the higher symmetry with five molecules in the asymmetric
unit initially with REFMAC [64] and then with Phenix.refine [65]. The final model was
obtained after cycles of manual adjustments using Coot software [63], then validated and
deposited in the Protein Data Bank [22] with the accession ID 6SMK. All model refinement
statistics are presented in Table S3.
4.7. Modelling of the EnpACD Substrate Complex
To obtain information on the interactions of the substrate with the particular subsites
of the enzyme, we docked tetrapeptide substrate consisting of the residues from the
stem peptide and the cross-bridge of the E. faecalis (L-Lys-D-Ala-L-Ala-L-Ala) in EnpACD
coordinates. The substrate was chosen based on the data about EnpACD specificity [18].
The substrate was manually docked into the EnpA binding groove based on structural data
of phosphinate tetrapeptide bound to LytM [33] and phosphinate dipeptide bound to the
VanXYg protein in a manner to place the D-Ala–L-Ala scissile bond in the active site center.
4.8. Enzymatic Activity Assays
Turbidity reduction assays. Bacterial strains were grown in a liquid tryptic soy broth
(TSB) medium and collected in a logarithmic phase when the cultures reached OD620
of 0.6–0.8. Bacterial cells were centrifuged and suspended in buffer C (50 mM glycine,
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pH 8.0) to OD620 of 2.0. On a 96 well plate, 100 µL of cell suspension was mixed with
100 µL of enzyme in buffer C supplemented with NaCl, whenever needed. The standard
concentration of EnpACD in the reaction mixture was 500 nM unless otherwise stated. In
the control samples, bacterial suspensions were mixed with 100 µL of buffer C. OD620 of
the reaction was monitored in The Infinite® F50 plate reader (TECAN) at room temperature
every 10 min for 1 h. Each experiment was repeated three times using an enzyme from
the same preparation and different bacterial cultures. Three technical repetitions were
prepared each time. The decrease in OD620 after one hour was calculated as a percentage
of the OD620 in the control without enzyme. The difference in the OD620 in the control
between time 0 and after 1 h incubation is due to autolysis.
CFU/mL reduction assays. Exponentially growing bacteria (OD620 = 0.6–0.8) were
suspended in buffer C at a concentration between 106–108 CFU/mL depending on the
experiments before the addition of the enzyme. At defined time points, 100 µL aliquots
were diluted and plated on TSB-agar plates. The number of colonies was counted after
overnight incubation at 37 ◦C, and the CFU/mL calculated. The control reaction was run
in parallel but without the enzyme.
4.9. FTIR
Tested proteins were purified according to the protocol described above. After the
final purification step, enzymes were concentrated on Amicon Ultra filters (10k MWCO).
Protein concentrations were 9.5 and 14.3 g/L for wild type and protein with R21Y substi-
tution, respectively. The FT-IR Spectrometer (Bruker, TENSOR 27) was calibrated against
filtrate obtained during sample preparation, which allowed to separate the noise (buffer
components) from the signal generated by the proteins. For the measurement, 20–30 µL of
each protein solution was used. The results were analyzed using OPUS software.
5. Conclusions
We defined conditions for effective lysis of pathogenic bacteria by EnpACD, demon-
strating a great bacteriolytic potential of the enzyme, which has much broader specificity as
compared to the previously characterized counterparts, but its activity is limited by ionic
conditions. At the same time, a comparative analysis of the structural and biochemical data
of EnpACD allowed us to describe the structure–function relationship in M23 enzymes.
This new information might help in the structure-based engineering of EnpACD and related
bacteriolytic enzymes in order to modulate their specificity and generate desired activity
that could be used to eradicate pathogenic bacteria and those resistant to antibiotics or
other bacteriolytic proteins.
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